Trial Profile
A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms OReO; OReO/ENGOT Ov-38
- Sponsors AstraZeneca
- 03 Oct 2023 Results evaluating the efficacy and safety of Maintenance olaparib rechallenge , published in the Annals of Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 16 Mar 2022 This trial has been completed in Belgium (End Date: 17 Feb 2022), according to European Clinical Trials Database record.